1 min read
Add as a preferred source on Google

SELLAS Life Sciences Shares Surge More Than 281% After Trial Results

The Phase 3 REGAL trial showed improved overall survival among patients with acute myeloid leukemia.

An unmarked vaccine vial beside an empty treatment chair / TokenPost.ai (macro)
An unmarked vaccine vial beside an empty treatment chair / TokenPost.ai (macro)

SELLAS Life Sciences shares surged more than 281% after the company announced positive results from its Phase 3 REGAL leukemia trial, which involved patients with acute myeloid leukemia.

SELLAS shares, which trade on Nasdaq as SLS, climbed above $28.

Trading volume exceeded 200 million shares.

The REGAL trial showed an improvement in overall survival among patients with acute myeloid leukemia.

The survival improvement was statistically significant.

Enna Lee

Reporter

Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…